Abstract 4295
Background
Founder BRCA1/2 cancer predisposing mutations have been reported in Italian population. We reported the founder BRCA1 mutation, c.4117G>T - p.Glu1373*, recurring in unrelated families of Abruzzo and Lazio regions of Central Italy.
Methods
Preliminary analysis of 17 unrelated families carrying BRCA1 c.4117G>T nonsense mutation reported in the Hereditary Breast/Ovarian Cancer Registry of the Oncology Territorial Care Unit, University of L’Aquila and Genetic Unit, Catholic University of Rome was performed by genetic counselling and peripheral blood collection after written informed consent from affected and unaffected probands. BRCA1/2 genetic analysis were performed by direct sequencing; haplotype analysis was carried out using microsatellite markers in the 17q21 region: D17S846, D17S1328, D17S855 (intragenic), D17S902, D17S806. Post-test genetic counselling was performed to address Therapeutic and/or Preventive Clinical strategies. Geographic area of origin, cancer family trees, cancers affecting the probands were collected. To date, overall 23 unrelated families were enrolled.
Results
In the preliminary analysis, BRCA1 c.4117G>T mutation was identified in 17 unrelated families with familial origin in a territory of Central Italy including Abruzzo and Lazio regions: this mutation was always and significantly associated with the Allelic Variant (AV) BRCA1, c.3119G>A (p.Ser1040Asn), in 52 tested carriers, 20 affected and 32 unaffected. Microsatellite markers confirmed a common haplotype shared by the 52 probands, comprising the region between D17S1328 and D17S902 markers. In overall 23 unrelated families, the association of BRCA1 founder mutation and the AV were identified in 66 tested carriers, 28 affected and 38 unaffected.
Conclusions
The BRCA1 c.4117G>T is a founder mutation prevalent in the territory of Central Italy in Abruzzo and southern Lazio regions, cosegregating with AV BRCA1 c.3119G>A, providing faster identification of affected and unaffected carriers to specifically address therapeutic and preventive clinical pathways for breast, ovarian and BRCA1-related cancers.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Enrico Ricevuto.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2494 - CAR-T Nursing Education at a UK Specialist Cancer Hospital
Presenter: Rose Ellard
Session: Poster Display session 3
Resources:
Abstract
2438 - Professional Quality of Life, Perceived Stress and Psychological Resistance Levels of Oncology-Hematology Nurses and the Factors Affecting
Presenter: Tugba Pehlivan
Session: Poster Display session 3
Resources:
Abstract
3541 - Representation of cancer survivors’ preferences in policies for supportive care: Implications for oncology nursing
Presenter: Samantha Mayo
Session: Poster Display session 3
Resources:
Abstract
5093 - Vaginal moisturizing post PDR-Pulse Dose Rate Brachytherapy.
Presenter: Pilar Fernández
Session: Poster Display session 3
Resources:
Abstract
1066 - The stomized, chemo and radiotreated patient vs untreated patient: complications and comparison with data literature
Presenter: Cristoforo Ferrero
Session: Poster Display session 3
Resources:
Abstract
1724 - Evaluating the role of clinical nurse specialist
Presenter: Anita Zeneli
Session: Poster Display session 3
Resources:
Abstract
3753 - Role of the Advanced Practice Nurse (APN) in a Functional Unit for Lung cancer at the Catalan Institute of Oncology
Presenter: Isabel Brao
Session: Poster Display session 3
Resources:
Abstract
2676 - A bottom-up approach for prioritising the scientific activities of the Italian Association of Cancer Nurses (AIIAO): rationale and topic identification
Presenter: Valentina Biagioli
Session: Poster Display session 3
Resources:
Abstract
575 - Investigating quality of care for people with cancer and dementia
Presenter: Naomi Farrington
Session: Poster Display session 3
Resources:
Abstract
5578 - Two years of BRCA1 and BRCA2 somatic External Quality Assessment with Gen&tiss Tiss scheme in France
Presenter: Kelly Dufraing
Session: Poster Display session 3
Resources:
Abstract